Eli Lil­ly picks up an­oth­er Covid-19 EUA as reg­u­la­tors wave through its Olu­mi­ant plus remde­sivir com­bo

Eli Lil­ly has picked up an­oth­er win at the FDA, cross­ing the fin­ish line again in the Covid-19 treat­ment race de­spite some mixed da­ta. And the au­tho­riza­tion comes be­fore Re­gen­eron’s an­ti­body ther­a­py, which no­tably was used to treat Pres­i­dent Don­ald Trump back in Oc­to­ber, could pick up an EUA.

Reg­u­la­tors have giv­en the green light to Lil­ly’s Olu­mi­ant, in com­bi­na­tion with Gilead’s remde­sivir, to treat sus­pect­ed or con­firmed Covid-19 cas­es in both hos­pi­tal­ized adults and chil­dren over 2 that need sup­ple­men­tal oxy­gen, ven­ti­la­tors or life sup­port. The au­tho­riza­tion was based on da­ta show­ing the me­di­an time to re­cov­ery from Covid-19 was sev­en days on the com­bo vs. eight days for remde­sivir by it­self.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.